Skip to main content

Table 1 Patient baseline characteristics in included studies

From: Extrapyramidal adverse events and anticholinergics use after the long-term treatment of patients with schizophrenia with the new long-acting antipsychotic Risperidone ISM®: results from matching-adjusted indirect comparisons versus once-monthly formulations of Paliperidone palmitate and Aripiprazole monohydrate in 52-week studies

Study (reference)

PRISMA-3 OLE [24]

Gopal 2010 [29]

Kane 2012 [30]

Patient cohort

Unstablea N = 55

Stabilizedb N = 119

Stablec N = 41

All N = 215

All N = 388

AOM arm N = 269

Age [Mean (SD)]

38.2 (10.0)

40.3 (11.5)

36.7 (9.9)

39.1 (10.9)

37.3 (10.8)

40.1 (11.0)

Sex [n (%)]

Male

31 (56.4)

76 (63.9)

24 (58.5)

131 (60.9)

209 (54.0)

162 (60.2)

Female

24 (43.6)

43 (36.1)

17 (41.5)

84 (39.1)

179 (46.0)

107 (39.8)

Race [n (%)]

White

44 (80.0)

97 (81.5)

41 (100.0)

182 (84.7)

269 (69.0)

152 (56.5)

Black

11 (20.0)

21 (17.6)

0 (0.0)

32 (14.9)

41 (11.0)

59 (21.9)

Asian

0 (0.0)

1 (0.8)

0 (0.0)

1 (0.5)

72 (19.0)

45 (16.7)

Other

0 (0.0)

0 (0.0)

0 (0.0)

0 (0.0)

6 (2.0)

13 (4.8)

Age at diagnosis [Mean (SD)]

27.7 (7.5)

28.5 (8.5)

27.9 (7.7)

28.2 (8.1)

26.8 (8.5)

25.8 (8.3)

PANSS total score [Mean (SD)]

82.3 (12.2)

70.0 (14.3)

60.3 (8.2)

71.3 (14.8)

58.2 (18.2)

54.5 (NR)

CGI-S score [Mean (SD)]

4.1 (0.9)

3.4 (0.9)

2.8 (0.5)

3.5 (0.9)

3.0 (median)

2.9 (NR)

BMI [Mean (SD)]

27.6 (4.7)

27.0 (4.9)

25.5 (3.7)

26.9 (4.7)

27.2 (5.6)

28.1 (6.9)

  1. AOM aripiprazole monohydrate once-monthly, BMI body mass index, CGI-S clinical global impressions—severity scale, DB double-blind, NR not reported, OLE open-label extension, PCB placebo, PANSS positive and negative syndrome scale, SD standard deviation
  2. a Unstable patients, PCB rollover patients from the DB phase of PRISMA-3 study who were randomly assigned to Risperidone ISM at dose of either 75 or 100 mg in the OLE phase
  3. b Stabilized patients, patients treated with Risperidone ISM in the DB phase who continued to receive monthly Risperidone ISM in the OLE phase at the same dose (75 or 100 mg) as during the DB phase
  4. c Stable patients, newly enrolled patients (de novo) who were on a previous stable maintenance dose of oral risperidone